| Code | CSB-RA004936MB17HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NG-350A, targeting CD40, a crucial costimulatory protein member of the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where it plays a pivotal role in regulating adaptive immune responses and inflammatory processes. Upon binding with its ligand CD154 (CD40L), CD40 initiates signaling cascades that promote B cell activation, antibody class switching, germinal center formation, and T cell priming. Dysregulation of CD40 signaling is implicated in various pathological conditions, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as B cell malignancies and solid tumors where it influences tumor microenvironment dynamics.
NG-350A is a genetically engineered oncolytic adenovirus that can infect tumor cells and express anti-CD40 agonist antibodies within them, strongly activating antigen-presenting cells such as dendritic cells, thereby initiating a systemic anti-tumor immune response. It is currently in clinical Phase I/II and is being evaluated for its safety, tolerability and preliminary efficacy in the treatment of advanced/metastatic epithelial cancer. This antibody is valuable for studies exploring immune cell interactions, inflammatory pathways, cancer immunology, and therapeutic target validation in preclinical models.
There are currently no reviews for this product.